What You Should Know:
- Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone.
- Orforglipron stands out as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
FDA Clears Dexcom G7 15 Day Continuous Glucose Monitoring System
What You Should Know:
- Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.
- The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and
Read More
DME Providers Lead to Better CGM Adherence and Lower Healthcare Costs Compared to Pharmacies
What You Should Know:
- New research published in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association, reveals that patients receiving continuous glucose monitors (CGM) through durable medical equipment (DME) providers demonstrate significantly higher adherence and lower healthcare costs compared to those using pharmacy channels.
- The study, titled "Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Healthcare Costs: A
Read More
Glooko Integrates Abbott FreeStyle Libre CGM, Enhancing Diabetes Management
What You Should Know:
- Glooko, a provider of integrated digital health solutions for diabetes management, has announced a significant expansion of its platform's capabilities with the integration of Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) systems in the United States.
- The newly implemented integration allows individuals with diabetes to seamlessly synchronize data from their FreeStyle Libre CGM systems with other vital health metrics, including insulin
Read More
Automated Insulin Delivery: Tandem Diabetes Unveils Control-IQ+ Enhancements
What You Should Know:
- Tandem Diabetes Care, a leader in insulin delivery and diabetes technology announced the U.S. commercial launch of Control-IQ+ technology.
- This update provides users with greater flexibility and control over their diabetes management. The expanded parameters and enhanced features of Control-IQ+ are designed to address a broader range of individual needs, making automated insulin delivery more accessible and effective.
Automated Insulin Delivery
Read More
Sequel Med Tech’s twiist AID System to Integrate Abbott’s FreeStyle Libre 3 Plus
What You Should Know:
- Sequel Med Tech, LLC, a company focused on developing cutting-edge insulin delivery technologies, has announced that its innovative twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, will be the first to integrate Abbott’s FreeStyle Libre 3 Plus sensor, a continuous glucose monitoring (CGM) device.
- The integration marks a pivotal moment for individuals with type 1 diabetes (T1D). The twiist AID System, expected to launch in Q2 2025, is
Read More
Senseonics and Ascensia Diabetes Care Integrate Eversense® 365 CGM with SweetSpot™ Platform
What You Should Know:
- Senseonics Holdings and Ascensia Diabetes Care today announced the integration of the Eversense® 365 Continuous Glucose Monitoring (CGM) System with the SweetSpot™ diabetes management platform in the U.S.
- The collaboration aims to improve patient care and streamline diabetes management for endocrinology practices and their patients.
Enhance Diabetes Management and Improve Patient Outcomes
The integration allows SweetSpot to seamlessly access and
Read More
Tandem Diabetes Care Receives FDA Clearance for Control-IQ+ Technology for Type 2 Diabetes
What You Should Know:
- Tandem Diabetes Care, a insulin delivery and diabetes technology company, announced that its Control-IQ+ technology has received clearance from the U.S. Food and Drug Administration (FDA) for use by adults with type 2 diabetes.
- The expanded indication builds on the success of Control-IQ+ in type 1 diabetes and offers a new automated insulin delivery (AID) option for individuals with type 2 diabetes.
Improve Glycemic Control for Adults with Type 2
Read More
GoodRx: The Average Price Per Insulin Unit Dropped 42%
What You Should Know:
- The average price per insulin unit dropped 42%, from $0.33 in 2019 to $0.19, in mid-2024, according to a new report from GoodRx. The drop represent the lowest average recorded in a decade.
- Thanks to the Inflation Reduction Act and voluntary price cuts by major insulin manufacturers, prices have seen significant declines. Products like Lantus, Novolin N, Humalog, and Humulin N are now more affordable than they have been in years.
Insulin Costs
Read More
Dexcom Introduces Generative AI Platform for Glucose Biosensing
What You Should Know:
- Dexcom, the global leader in continuous glucose monitoring (CGM), has achieved another groundbreaking milestone by launching the first generative AI (GenAI) platform in glucose biosensing technology, Stelo.
- The Stelo platform analyzes individual health data patterns to provide personalized insights and recommendations for improving metabolic health.
AI-Powered Personalized Guidance
The Dexcom GenAI platform leverages Google Cloud's Vertex AI and
Read More
